Federal contract award
75A50124C00047
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $18.8M |
| Current contract value | $18.8M |
| Potential contract value / ceiling | $121.5M |
| Start date | Sep 30, 2024 |
| Current end date | Sep 30, 2026 |
| Potential end date | Dec 22, 2031 |
| Latest award activity | Sep 26, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 26, 2025 | P00004 | $1.9M | SUPPLEMENTAL FUNDING FOR CLIN 0001; UPDATE THE POP FOR CLINS 0001 - 0007; UPDATE THE SOW AND MILESTONE TABLE ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY A |
| Aug 19, 2025 | P00003 | $0 | NCE FOR CLIN 0001 TO END ON 10/30/2025; UPDATE FOR TITLE TO ADD CHIEF EXECUTIVE OFFICER (CEO) FOR LAURA SAWARD; UPDATE POC FOR CPARS, AND UPDATE OF FAR CLAUSES BASED ON EXECUTIVE ORDERS ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), |
| Jan 10, 2025 | P00002 | $0 | ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR |
| Oct 31, 2024 | P00001 | $0 | ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR |
| Sep 26, 2024 | 0 | $16.9M | ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR |
Estimated positioning window
Dec 22, 2030 – Jun 22, 2031
45/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 45/100. Available recorded signals: 40 points.
- Contract end 2031-12-22 (1877 days from calculation)
- +5 points
- 18 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2025-09-26
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 20, 2026 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 19, 2026 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | May 29, 2025 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Dec 18, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | May 31, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Apr 23, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 29, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Dec 22, 2023 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Nov 9, 2023 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Sep 26, 2023 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.